Outlook Therapeutics (OTLK) EBT Margin (2015 - 2025)

Outlook Therapeutics (OTLK) reported EBT Margin of 16175.93% for Q3 2025, up 1308.29% quarter-over-quarter from 1338.75% in Q2 2025.

Outlook Therapeutics (OTLK) EBT Margin (2015 - 2025) Analysis & Trends

Outlook Therapeutics (OTLK) has 6 years of EBT Margin data on file, last reported at 16175.93% in Q3 2025.

  • EBT Margin for Q3 2025 came in at 16175.93%, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was 1311.45% (changed N/A YoY), and the FY2025 annual result was 4526.01%, changed N/A from the prior year.
  • EBT Margin climbed to 16175.93% in Q3 2025 per OTLK's latest filing, from 1338.75% in the prior quarter.
  • Over five years, EBT Margin peaked at 16175.93% in Q3 2025 and troughed at 1338.75% in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Alterity Therapeutics 719,706.53 Bn 719,706.50 Bn - -
2 Belite Bio 55,800.00 Bn 55,800.00 Bn - -
3 Quantum Biopharma 18,182.30 Bn 18,182.29 Bn - -
4 Legend Biotech 3,154.00 Bn 3,153.71 Bn 242.10 Mn 6.40%
5 Akari Therapeutics 1,844.30 Bn 1,844.29 Bn - -
6 Evaxion A 1,567.96 Bn 1,567.94 Bn - -
7 Psyence Biomedical 251.43 Bn 251.42 Bn - -
8 Vertex Pharmaceuticals 112.56 Bn 105.31 Bn 2.59 Bn 41.95%
9 Abivax 94.37 Bn 94.37 Bn - -
10 Outlook Therapeutics 51.56 Mn 43.81 Mn -21,888.00 -

Historic Data

Download Data
DateValue
Sep 30, 2025 16,175.93%
Jun 30, 2025 -1,338.75%
Sep 30, 2019 -217.47%
Jun 30, 2019 -893.79%
Mar 31, 2019 -1,597.90%
Dec 31, 2018 -912.50%
Sep 30, 2018 -1,644.94%
Jun 30, 2018 -1,092.37%
Mar 31, 2018 -976.81%
Dec 31, 2017 -656.99%
Sep 30, 2017 -202.47%
Jun 30, 2017 -1,758.72%
Mar 31, 2017 -2,654.21%
Dec 31, 2016 -6,298.89%
Sep 30, 2016 -2,135.40%
Jun 30, 2016 -4,511.46%
Mar 31, 2016 -350.98%
Dec 31, 2015 -1,689.85%
Sep 30, 2015 -3,647.43%
Jun 30, 2015 -895.87%